Omecamtiv Mecarbil Fails to Improve Exercise Capacity in HFrEF

Despite earlier successes, the experimental agent was no better than placebo in improving exercise capacity in the phase 3 METEORIC-HF trial.
Medscape Medical News

source https://www.medscape.com/viewarticle/978355?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

Heart Failure Care Outside of ICU Can Lower Cost